rs7649970 — PPARG PPARG C-689T

PPARG PPARγ2 P2 promoter variant that reduces basal promoter activity, elevating LDL-cholesterol and increasing coronary artery disease risk independently of traditional cardiovascular risk factors

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG C-689T — The Promoter Dimmer in the PPARγ2 Isoform

The PPARG gene encodes PPARγ11 PPARγ
Peroxisome Proliferator-Activated Receptor Gamma — a nuclear receptor that controls adipocyte differentiation, fat storage, insulin sensitisation, and lipid metabolism throughout the body, the master regulator of fat-cell biology. The gene has multiple isoforms generated from distinct promoters. The C-689T variant (rs7649970) sits in the P2 promoter — the one that exclusively drives expression of the PPARγ2 isoform22 PPARγ2 isoform
PPARγ2 is distinguished from PPARγ1 by a 28-amino-acid N-terminal extension and is expressed almost exclusively in adipose tissue, where it is the dominant regulator of adipogenesis and insulin sensitisation, which is predominant in adipose tissue and is the isoform studied in the landmark Pro12Ala literature. Unlike Pro12Ala (rs1801282), which changes the receptor protein itself, C-689T changes how much of the protein gets made in the first place.

The Mechanism

The C-689T polymorphism is a C-to-T transition at position -689 in the PPARγ2 P2 promoter, within a region that contains a putative GATA transcription factor33 GATA transcription factor
GATA factors (GATA2, GATA3) are zinc-finger transcription factors that bind GATA DNA sequences and regulate gene expression in adipose, hematopoietic, and endothelial cells binding site. Meirhaeghe et al. (2005)44 Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 demonstrated that GATA2 and GATA3 proteins bind the wild-type C-689 site but fail to bind the mutated T-689 site. The key consequence: the T allele renders the P2 promoter less active at baseline, resulting in reduced PPARγ2 expression in adipose tissue. Reduced PPARγ2 impairs adipocyte differentiation and insulin sensitisation capacity, shifting the metabolic balance toward higher circulating LDL-cholesterol, elevated triglycerides, and atherogenic lipid profiles.

The Evidence

The discovery study by Meirhaeghe et al. (2005)55 Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 examined 1,155 French subjects and found that T allele carriers had significantly elevated body weight and LDL-cholesterol concentrations compared with CC homozygotes. A haplotype analysis showed that when C-689T interacts with the C1431T and Pro12Ala variants in a specific haplotype combination, the association with higher LDL and body weight is amplified.

Two Chinese Han studies quantified the cardiovascular risk directly. Li et al. (2008)66 Li et al. (2008)
Li JP et al. Study on the association of -689C/T polymorphism in the PPARgamma2 promoter with myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2008 enrolled 194 myocardial infarction patients and 693 controls and found the T allele was an independent risk factor for MI (OR 2.13, 95% CI 1.21–3.74, P = 0.009) after adjusting for traditional risk factors. T allele carriers also showed significantly elevated total cholesterol. Li et al. (2017)77 Li et al. (2017)
Li JP et al. Functional variant of C-689T in the peroxisome proliferator-activated receptor-γ2 promoter is associated with coronary heart disease in Chinese nondiabetic Han people. Chin Med Sci J, 2017 extended this to 455 CHD patients and 693 controls without CHD, finding the T allele independently associated with CHD (OR 1.67, 95% CI 1.03–2.71, P = 0.037) and confirmed elevated total cholesterol in T carriers.

A European replication came from Dallongeville et al. (2009)88 Dallongeville et al. (2009)
Dallongeville J et al. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res, 2009 using the PRIME study cohort (249 CHD cases, 494 controls; middle-aged men from France and Northern Ireland). TT homozygotes showed OR 3.43 (95% CI 0.96–12.27, P = 0.058) — statistically marginal owing to the rarity of TT, but biologically consistent with the Chinese data. In a haplotype study of 1,155 French subjects, Meirhaeghe et al. (2005, Diabetes)99 Meirhaeghe et al. (2005, Diabetes)
Meirhaeghe A et al. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes, 2005 found that a haplotype carrying the T allele was enriched in metabolic syndrome cases (OR up to 2.47).

Practical Implications

The T allele is carried by roughly 13% of Europeans and 17% of Africans, making CT heterozygotes (~23% of Europeans) a sizeable group for whom LDL monitoring and lipid management are specifically warranted. The TT homozygote (roughly 2% of the population globally) carries the highest expression deficit but is too rare for well-powered homozygote-specific trials. The primary actionable markers are LDL-cholesterol and total cholesterol — both consistently elevated in T allele carriers across populations.

Interactions

rs7649970 is one of four common PPARG variants that co-segregate in haplotype blocks. The most clinically relevant interactions are with rs1801282 (Pro12Ala) and rs3856806 (C1431T). The G-T-Ala haplotype (rs10865710 G / rs7649970 T / rs1801282 Ala) was associated with the highest LDL and body weight burden in the Meirhaeghe 2005 cohort. Additionally, rs7649970 and rs10865710 act through independent mechanisms — rs10865710 disrupts a CREB2 enhancer element while rs7649970 disrupts GATA binding in the PPARγ2 P2 promoter — meaning carriers of risk alleles at both loci face compounded suppression of PPARγ expression via separate molecular paths.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard PPARγ2 Promoter Activity Normal

Common genotype — normal PPARγ2 P2 promoter activity

You have two copies of the reference C allele at this PPARγ2 promoter site, shared by approximately 75% of the global population. The GATA binding site in the P2 promoter is intact, supporting baseline PPARγ2 expression in adipose tissue. This genotype is not associated with elevated LDL-cholesterol or increased coronary artery disease risk from this variant specifically.

CT Reduced PPARγ2 Promoter Activity Intermediate

One T allele — moderately reduced PPARγ2 P2 promoter activity

The C-689 site in the PPARγ2 P2 promoter contains a GATA transcription factor binding motif. GATA2 and GATA3 proteins bind the wild-type C allele but fail to bind the T mutant site (Meirhaeghe et al., PMID 15896659). The result is reduced basal promoter activity, leading to lower PPARγ2 levels in adipose tissue. Because PPARγ2 is the primary driver of adipocyte insulin sensitisation, its reduction impairs lipid partitioning — reflected as elevated circulating LDL-cholesterol and total cholesterol. This lipid dysregulation mechanism is distinct from Pro12Ala (rs1801282), which reduces receptor function rather than expression.

TT Low PPARγ2 Promoter Activity High Risk

Two T alleles — substantially reduced PPARγ2 P2 promoter activity

The TT genotype eliminates GATA factor binding at both copies of the P2 promoter GATA site, resulting in the maximum reduction of basal PPARγ2 expression. The haplotype analysis by Meirhaeghe et al. (2005, Diabetes) found that rare alleles of C-689T combined with specific haplotype backgrounds (including the 1431CC genotype) showed the highest metabolic syndrome risk (OR up to 2.47), suggesting that TT homozygosity in the right haplotype context produces a compounding metabolic burden. Although TT is too rare for well-powered homozygote-specific randomised trials, the biological logic — two disrupted GATA sites versus one — supports the stepwise elevation in risk observed across genotypes. Because PPARγ is also the pharmacological target of thiazolidinedione drugs (pioglitazone), TT carriers with type 2 diabetes have a mechanistic rationale to discuss this class with their clinician.